The GPR75 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human KYSE-30 esophageal squamous cell carcinoma line, offering a powerful loss-of-function model for investigating the orphan G protein-coupled receptor GPR75. This product delivers a genetically heterogeneous pool of cells with targeted disruption of the GPR75 locus, enabling robust functional studies without the limitations of clonal selection. The polyclonal format preserves the inherent biological diversity of the parental line while effectively ablating GPR75 expression, making it suitable for population-level analyses of signaling and metabolic phenotypes.
The parental KYSE-30 cell line was originally established from a well-differentiated invasive esophageal squamous cell carcinoma and is widely employed as a preclinical model in esophageal cancer research. KYSE-30 cells retain key characteristics of the tumor of origin, including epithelial morphology and aggressive growth properties, providing a relevant context for exploring the intersection of oncogenic signaling and metabolic regulation. This host background is particularly valuable for dissecting how GPR75-mediated pathways contribute to cancer cell metabolism, invasion, and response to metabolic cues.
GPR75 functions as a G??q/11-coupled receptor that, upon activation by upstream regulators such as CCL5, leptin, or insulin, stimulates phospholipase C-?? (PLC-??) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). This leads to intracellular calcium mobilization and protein kinase C (PKC) activation, ultimately modulating energy homeostasis and insulin sensitivity through downstream effectors including AMPK, IRS1, and AKT. The receptor interacts with regulatory proteins like ??-arrestin2 and GPCR kinase 2 (GRK2), which mediate desensitization and internalization. In the knockout cells, ablation of GPR75 disrupts this entire signaling cascade, permitting rigorous interrogation of its role in metabolic and mitogenic pathways.
In the context of esophageal squamous cell carcinoma, GPR75 signaling may integrate metabolic status with cancer progression. Leptin and insulin are known to influence tumor cell proliferation and survival, and their crosstalk with GPR75 could be critical in obesity-related cancer risk. The GPR75 Knockout KYSE-30 Polyclonal Cells provide a unique tool to disentangle the contributions of this orphan receptor to cancer cell metabolism, migration, and invasion, and to evaluate whether GPR75 blockade offers therapeutic potential in esophageal malignancies. These cells are particularly suited for comparative analyses with parental KYSE-30 cells to identify GPR75-dependent phenotypes.
Researchers can apply this knockout model to a broad range of functional studies, including metabolic disease modeling, obesity and type 2 diabetes research, and drug target validation. Representative assays such as phospho-AMPK and phospho-AKT western blotting, calcium flux measurements, glucose uptake assays, and cell proliferation or migration assays enable detailed phenotypic characterization. Additionally, RNA-seq and CRISPR knockout validation by Sanger sequencing confirm gene disruption and facilitate transcriptomic profiling. For further details on experimental protocols and validation data, please contact Ascent Research.
